EZH2 and leukemia: Separately, EZH2 inhibitors combined with glucocorticoids or combination chemotherapy were reported as a promising treatment strategy for relapsed ALL with NSD2 mutations [60], providing further evidence that manipulation of PRC2 function might be therapeutically beneficial in some leukaemia subtypes.